The University of Minnesota Eastern Cooperative Oncology Group (ECOG) Program is a multimodality research activity comprised of 3 components: a member institution (U of Minnesota Hospitals and V. A. Medical Center), a CGOP and a CCOP. Multidisciplinary programs are the best equipped to participate in cancer clinical trials research at the cooperative group level. This program includes radiotherapists, medical oncologists, surgeons, cancer immunologists, molecular biologists, pathologists, a gastroenterologist and an infectious disease expert specializing in AIDS. Accrual is markedly increased and demonstrates participation in the full range of ECOG studies. This Program makes extensive contributions to the scientific and administrative leadership of the Group. Committees chaired or cochaired by members of this program 1984-1988 include Hematology, GU, Head and Neck, Data Managers, Ethics, Audit and BMT. Members of this program serve on the Executive Committee, the Community Cancer Steering Committee and the Nominating Committee. We chaired/co- chaired 21 protocols and are listed as authors in 34 ECOG papers and abstracts during the current grant period. The Minnesota Program led in establishing a sophisticated ECOG resource laboratory system in myeloma and leukemia tumor biology and has been successful in developing programs in ECOG to combine BRMs with chemotherapy. This Program's consistency and growth derives from sound organizational stability and committed multidisciplinary membership. The recently issued CTEP Cooperative Group Guidelines listed the 11 attributes important for primary member programs. These were: 1) active participation in Group's scientific committees, 2) service as study chairs, 3) contribution of independent lab research, 4) participation in Group meetings, 5) accrual, 6) prompt, accurate data submission, 7) authorship/presentation of results, 8) participation in Group audit program, 9) service on Group administrative committees, 10) service on NCI site visit and peer review teams. 11) assuming responsibility for affiliates. These literally define the 11 major strengths of this ECOG Program. A vigorous ECOG program is essential to the effective utilization of the extensive patient base and scientific resources in this area for clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA020365-13
Application #
3556521
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1991-04-30
Budget Start
1990-08-09
Budget End
1991-04-30
Support Year
13
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Forastiere, A A; Leong, T; Rowinsky, E et al. (2001) Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19:1088-95
Harris, J E; Ryan, L; Hoover Jr, H C et al. (2000) Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 18:148-57
Oken, M M; Leong, T; Lenhard Jr, R E et al. (1999) The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer 86:957-68
Wiernik, P H; Phillips, V; Camacho, F J et al. (1998) Methylguazone, vindesine and cisplatin for the treatment of patients with relapsed or refractory malignant lymphoma: an Eastern Cooperative Oncology Group Study (PA482). Leuk Lymphoma 30:619-24
Paietta, E; Van Ness, B; Bennett, J et al. (1992) Lymphoid lineage-associated features in acute myeloid leukaemia: phenotypic and genotypic correlations. Br J Haematol 82:324-31
Weisdorf, D J; Andersen, J W; Glick, J H et al. (1992) Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation. J Clin Oncol 10:942-7
Paietta, E; Van Ness, B; Le Beau, M M et al. (1992) Translocation (2;9)(p12;p23) in a case of acute leukemia with t(4;11)(q21;q23). Lack of rearrangement of the kappa and interferon gene loci. Cancer Genet Cytogenet 60:82-5
Paietta, E; Van Ness, B; Bennett, J M et al. (1991) Unexpected immunoglobulin light chain gene rearrangements in myeloid antigen positive acute lymphoid leukemia. Leuk Res 15:149-55
Tormey, D C; Gray, R; Gilchrist, K et al. (1990) Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer 65:200-6
Feddersen, R M; Martin, D J; Van Ness, B G (1990) The frequency of multiple recombination events occurring at the human Ig kappa L chain locus. J Immunol 144:1088-93

Showing the most recent 10 out of 15 publications